Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients

C. Montecucco, A. Mazzone, D. Pasotti, R. Caporali, M. Longhi, D. Casilli, G. Ricevuti, P. Fratino, M. P. Ruffilli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The effect of piroxicam therapy (20 mg/day for 15 days) on various polymorphonuclear granulocyte (PMN) responses and on PMN elastase concentration was investigated in nine patients with active rheumatoid arthritis. Peripheral biood and synovial fluid samples were collected before starting therapy and 12 h after the last dose of the drug. All patients were evaluable for peripheral blood analysis and six for synovial fluid analysis. Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. This seems mainly due to an effect on FMLP binding, as no differences were observed after therapy in PMA- and PHA-induced aggregation as well as in serum-induced chemotaxis. In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2 -) production was found after piroxicam therapy. This effect was as evident in peripheral blood as in synovial fluid PMN. Also, a significant reduction in synovial fluid PMN number and synovial fluid PMN elastase concentration (elastase-α1-proteinase complex) was found after treatment. It is concluded that piroxicam may act at different sites on various PMN responses-Its effect on O2 - generation and PMN elastase concentration in synovial fluid may have an important role in reducing destruction of arthritic joint tissue.

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalInflammation
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 1989

Fingerprint

Piroxicam
Leukocyte Elastase
Synovial Fluid
Granulocytes
Rheumatoid Arthritis
Chemotaxis
Therapeutics
Pancreatic Elastase
Phagocytosis
Superoxides
Arthritis
Peptide Hydrolases
Joints
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology
  • Cell Biology

Cite this

Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients. / Montecucco, C.; Mazzone, A.; Pasotti, D.; Caporali, R.; Longhi, M.; Casilli, D.; Ricevuti, G.; Fratino, P.; Ruffilli, M. P.

In: Inflammation, Vol. 13, No. 2, 04.1989, p. 211-220.

Research output: Contribution to journalArticle

Montecucco, C. ; Mazzone, A. ; Pasotti, D. ; Caporali, R. ; Longhi, M. ; Casilli, D. ; Ricevuti, G. ; Fratino, P. ; Ruffilli, M. P. / Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients. In: Inflammation. 1989 ; Vol. 13, No. 2. pp. 211-220.
@article{5b1545f5ed5f4ac9a7283c1481336197,
title = "Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients",
abstract = "The effect of piroxicam therapy (20 mg/day for 15 days) on various polymorphonuclear granulocyte (PMN) responses and on PMN elastase concentration was investigated in nine patients with active rheumatoid arthritis. Peripheral biood and synovial fluid samples were collected before starting therapy and 12 h after the last dose of the drug. All patients were evaluable for peripheral blood analysis and six for synovial fluid analysis. Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. This seems mainly due to an effect on FMLP binding, as no differences were observed after therapy in PMA- and PHA-induced aggregation as well as in serum-induced chemotaxis. In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2 -) production was found after piroxicam therapy. This effect was as evident in peripheral blood as in synovial fluid PMN. Also, a significant reduction in synovial fluid PMN number and synovial fluid PMN elastase concentration (elastase-α1-proteinase complex) was found after treatment. It is concluded that piroxicam may act at different sites on various PMN responses-Its effect on O2 - generation and PMN elastase concentration in synovial fluid may have an important role in reducing destruction of arthritic joint tissue.",
author = "C. Montecucco and A. Mazzone and D. Pasotti and R. Caporali and M. Longhi and D. Casilli and G. Ricevuti and P. Fratino and Ruffilli, {M. P.}",
year = "1989",
month = "4",
doi = "10.1007/BF00924791",
language = "English",
volume = "13",
pages = "211--220",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients

AU - Montecucco, C.

AU - Mazzone, A.

AU - Pasotti, D.

AU - Caporali, R.

AU - Longhi, M.

AU - Casilli, D.

AU - Ricevuti, G.

AU - Fratino, P.

AU - Ruffilli, M. P.

PY - 1989/4

Y1 - 1989/4

N2 - The effect of piroxicam therapy (20 mg/day for 15 days) on various polymorphonuclear granulocyte (PMN) responses and on PMN elastase concentration was investigated in nine patients with active rheumatoid arthritis. Peripheral biood and synovial fluid samples were collected before starting therapy and 12 h after the last dose of the drug. All patients were evaluable for peripheral blood analysis and six for synovial fluid analysis. Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. This seems mainly due to an effect on FMLP binding, as no differences were observed after therapy in PMA- and PHA-induced aggregation as well as in serum-induced chemotaxis. In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2 -) production was found after piroxicam therapy. This effect was as evident in peripheral blood as in synovial fluid PMN. Also, a significant reduction in synovial fluid PMN number and synovial fluid PMN elastase concentration (elastase-α1-proteinase complex) was found after treatment. It is concluded that piroxicam may act at different sites on various PMN responses-Its effect on O2 - generation and PMN elastase concentration in synovial fluid may have an important role in reducing destruction of arthritic joint tissue.

AB - The effect of piroxicam therapy (20 mg/day for 15 days) on various polymorphonuclear granulocyte (PMN) responses and on PMN elastase concentration was investigated in nine patients with active rheumatoid arthritis. Peripheral biood and synovial fluid samples were collected before starting therapy and 12 h after the last dose of the drug. All patients were evaluable for peripheral blood analysis and six for synovial fluid analysis. Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. This seems mainly due to an effect on FMLP binding, as no differences were observed after therapy in PMA- and PHA-induced aggregation as well as in serum-induced chemotaxis. In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2 -) production was found after piroxicam therapy. This effect was as evident in peripheral blood as in synovial fluid PMN. Also, a significant reduction in synovial fluid PMN number and synovial fluid PMN elastase concentration (elastase-α1-proteinase complex) was found after treatment. It is concluded that piroxicam may act at different sites on various PMN responses-Its effect on O2 - generation and PMN elastase concentration in synovial fluid may have an important role in reducing destruction of arthritic joint tissue.

UR - http://www.scopus.com/inward/record.url?scp=0024313228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024313228&partnerID=8YFLogxK

U2 - 10.1007/BF00924791

DO - 10.1007/BF00924791

M3 - Article

C2 - 2547713

AN - SCOPUS:0024313228

VL - 13

SP - 211

EP - 220

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 2

ER -